Skip to content

Advertisement

  • Poster presentation
  • Open Access

Disease characteristics and medication use in a multicenter cohort of children with juvenile idiopathic arthritis (JIA): preliminary analyses from the CARRAnet registry

  • Sarah Ringold5,
  • Timothy Beukelman7,
  • Esi M Morgan DeWitt2,
  • Marc Natter1,
  • Peter A Nigrovic6,
  • Yukiko Kimura3 and
  • CARRAnet Investigators4
Pediatric Rheumatology201210(Suppl 1):A46

https://doi.org/10.1186/1546-0096-10-S1-A46

Published: 13 July 2012

Keywords

Juvenile Idiopathic ArthritisRheumatic DiseaseJoint DamageLonge Disease DurationBiologic DMARD

Purpose

The CARRAnet Registry, a multicenter registry of children with rheumatic diseases in the U.S. organized by the Childhood Arthritis Rheumatology and Research Alliance (CARRA), began enrollment in May 2010. Our aims were to describe the characteristics of children with JIA enrolled into the registry to date and to identify characteristics associated with the use of biologic disease-modifying anti-rheumatic drugs (DMARDs).

Methods

Data were extracted for all children with JIA who were enrolled up to December 28, 2010. Children who had ever received biologic DMARDs were compared to children who had not using relative risks (RR) and unpaired t-tests.

Results

1072 children with JIA were enrolled during the first 7 months by 26 centers. The categorical characteristics of the cohort are shown in Table 1 and the continuous characteristics of the cohort are shown in Table 2. 77% had received at least one non-biologic DMARD at enrollment, most commonly methotrexate. 69% had received corticosteroids during their disease course, most frequently intra-articular (49%) and daily oral (36%). 45% of the cohort received one or more biologic DMARD during their disease course. The proportion of patients who received specific biologic agents is shown in Table 3. Children receiving biologic DMARDs were older at enrollment (mean age 13 years versus 10 years; p <0.001) and had a longer disease duration (mean 6 years versus 4 years; p<0.001). Children with imaging evidence of joint damage (RR 1.6; 95% CI: 1.3-1.9), positive RF (RR: 1.36; 95% CI 1.1 – 1.6), or positive anti-CCP (RR: 1.35; 1.1-1.7) were more likely to have received a biologic DMARD. Children with oligoarthritis were less likely to have received a biologic DMARD than other categories.
Table 1

Table 1

Characteristuc

N (%)

JIA Category

 

Systemic

87 (8)

Polyarticular (RF-)

334 (31)

Polyarticular (RF+)

266 (25)

Extended Oligoarticular

91 (9)

Psoriatic

56 (5)

Enthesitis-Related

110 (10)

Undifferentiated

37 (3)

Other or unknown

14 (1)

Female

783 (73)

Race

 

White

965 (89)

Black or African American

62 (6)

Asian

29 (3)

Other

54 (5)

Ethnicity

 

Hispanic or Latino

101 (9)

Positic Serology

 

ANA

483 (45)

RF (initial)

88 (8)

RF (confirmatory)

46 (4)

Anti-CCP

51 (5)

HLA-B27

95 (9)

Uveitis

 

Current

46 (4)

Past

74 (7)

ACR Functional Class

 

Class I

872 (81)

Class II

179 (17)

Class III

28 (3)

Class IV

4 (<1)

Health-related quality of life

 

Excellent

242 (23)

Very good

437 (41)

Good

352 (33)

Poor

28 (3)

Very Poor

1 (<1)

Imaging evidence of joint damageI

265 (25)

Table 2

Table 2

Characteristic

Mean (Median)

Range

Age at enrollment (years)

11 (12)

<1 – 22

Age at symptom onset (years)

7 (5)

<1 – 16

Age at first rheumatology visit (years)

7 (7)

<1 – 21

Disease duration (years)

5 (4)

0 – 18

Duration between sympton onset and first rheumatology visit (years)

1 (<1)

0 – 12

Number of active joints

2 (0)

0 – 38

Physician global assessment of disease activity

2 (1)

0 – 9

Parent/patient assessment of disease acticity

2 (1)

0 - 10

Parent/patient assessment of overall well-being

2 (2)

0 – 9

Patrent/patient asessment of pain

3 (2)

0 – 10

CHAQ score

0.35 (0.125)

0 – 3

Table 3

Table 3

Biologic medication

Current use

Prior use

 

N (% of biologic users)

N (% of biologic users)

TNF-alpha inhibitirs

  

Adalimumab

78 (7)

70 (6)

Cartolizumab

4 (<1)

0

Etanercept

214 (20)

183 (17)

Gollimumab

5 (<1)

4 (<1)

Inflximab

46 (4)

46 (4)

IL-1 Inhibitors

  

Ankira

14 (1)

22 (2)

Rilonacept

2 (<1)

2 (<1)

Other biologic agents

  

Abatacept

24 (2)

8 (<1)

Rituximab

2 (<1)

8 (<1)

Tocilizumab

6 (<1)

0 (<1)

Conclusion

The majority of patients with JIA enrolled into the CARRAnet registry has relatively low disease activity, minimal disability, and have received at least one DMARD. Positive anti-CCP or RF, joint damage on imaging, older age at enrollment and longer disease duration were associated with biologic DMARD use. Limitations include the underrepresentation of non-English speaking families and enrollment bias. Continued enrollment into this cohort will support future analyses with increased sample sizes and the potential for longitudinal data analysis.

Disclosure

Sarah Ringold: None; Timothy Beukelman: None; Esi M. Morgan DeWitt: None; Marc Natter: None; Peter A. Nigrovic: None; Yukiko Kimura: None; CARRAnet Investigators: None.

Authors’ Affiliations

(1)
Children's Hospital Boston, Boston, USA
(2)
Cincinnati Children'sHospital, Cincinnati, USA
(3)
Hackensack University Medical Center, Hackensack, USA
(4)
, Stanford, USA
(5)
Seattle Children's Hospital, Seattle, USA
(6)
, Boston, USA
(7)
University of Alabama-Birmingham, Birmingham, USA

Copyright

© Ringold et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement